Vimarsana
Biggest News Aggregation in the World

Page 28 - Pharma Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Services Today - Breaking & Trending Today

Dillon & Associates Inc. Buys Shares of 8,000 NeoGenomics, Inc. (NASDAQ:NEO) - Vimarsana News

Dillon & Associates Inc. Buys Shares of 8,000 NeoGenomics, Inc. (NASDAQ:NEO)

Dillon & Associates Inc. bought a new stake in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 8,000 shares of the medical research company’s stock, valued at approximately $272,000. Other hedge funds and other […]

2023-07-18 | TSXV:THNK | Press Release | Think Research Corporation - Vimarsana News

2023-07-18 | TSXV:THNK | Press Release | Think Research Corporation

(2023-07-18 | TSXV:THNK) Think Research's Pharmapod Selected by Neighbourly Pharmacy to Manage Medication Safety for Nearly 300 Locations Across Canada

Lyophilization Services for Biopharmaceuticals: Global - Vimarsana News

Lyophilization Services for Biopharmaceuticals: Global

Dublin, July 14, 2023 (GLOBE NEWSWIRE) -- The Lyophilization Services for Biopharmaceuticals: Global Market Forecast to 2028 report has been added to ...

Clinical Trial Supplies Market to be Worth $3.4 Billion by 2030: Grand View Research, Inc. - Vimarsana News

Clinical Trial Supplies Market to be Worth $3.4 Billion by 2030: Grand View Research, Inc.

/PRNewswire/ -- The global clinical trial supplies market size is expected to reach USD 3.4 billion by 2030, expanding at 6.5% CAGR from 2023 to 2030,...

NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Recommendation of "Moderate Buy" from Brokerages - Vimarsana News

NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) have earned a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year target price […]